Equities research analysts expect Synlogic Inc (NASDAQ:SYBX) to report sales of $980,000.00 for the current quarter, Zacks reports. Five analysts have made estimates for Synlogic’s earnings. The lowest sales estimate is $300,000.00 and the highest is $3.13 million. Synlogic reported sales of $250,000.00 in the same quarter last year, which would suggest a positive year-over-year growth rate of 292%. The business is expected to issue its next earnings results on Wednesday, August 14th.
According to Zacks, analysts expect that Synlogic will report full-year sales of $1.96 million for the current year, with estimates ranging from $300,000.00 to $4.71 million. For the next fiscal year, analysts forecast that the company will report sales of $1.68 million, with estimates ranging from $1.30 million to $2.40 million. Zacks’ sales averages are an average based on a survey of analysts that follow Synlogic.
Synlogic (NASDAQ:SYBX) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.03. Synlogic had a negative net margin of 2,005.43% and a negative return on equity of 38.93%. The business had revenue of $0.34 million during the quarter, compared to the consensus estimate of $0.42 million.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN purchased a new stake in Synlogic in the 3rd quarter worth about $351,000. BlackRock Inc. purchased a new position in shares of Synlogic during the third quarter worth about $13,301,000. Fosun International Ltd purchased a new position in shares of Synlogic during the fourth quarter worth about $286,000. Bank of New York Mellon Corp purchased a new position in shares of Synlogic during the third quarter worth about $720,000. Finally, TIAA CREF Investment Management LLC purchased a new position in shares of Synlogic during the third quarter worth about $251,000. Institutional investors own 81.12% of the company’s stock.
NASDAQ:SYBX traded up $0.59 during trading hours on Friday, hitting $8.51. 140,140 shares of the company traded hands, compared to its average volume of 63,808. The company has a current ratio of 11.53, a quick ratio of 11.53 and a debt-to-equity ratio of 0.20. Synlogic has a one year low of $5.75 and a one year high of $14.59. The stock has a market cap of $201.08 million, a PE ratio of -4.19 and a beta of 2.40.
Synlogic Company Profile
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Featured Article: What is the LIBOR?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.